MDT

88.2

-0.16%↓

A

115.27

-0.9%↓

VEEV

156.75

-7.5%↓

HQY

82.69

+1.01%↑

TLRY

6.75

+0.75%↑

MDT

88.2

-0.16%↓

A

115.27

-0.9%↓

VEEV

156.75

-7.5%↓

HQY

82.69

+1.01%↑

TLRY

6.75

+0.75%↑

MDT

88.2

-0.16%↓

A

115.27

-0.9%↓

VEEV

156.75

-7.5%↓

HQY

82.69

+1.01%↑

TLRY

6.75

+0.75%↑

MDT

88.2

-0.16%↓

A

115.27

-0.9%↓

VEEV

156.75

-7.5%↓

HQY

82.69

+1.01%↑

TLRY

6.75

+0.75%↑

MDT

88.2

-0.16%↓

A

115.27

-0.9%↓

VEEV

156.75

-7.5%↓

HQY

82.69

+1.01%↑

TLRY

6.75

+0.75%↑

Начало・Списък с акции・Beam Therapeutics Inc

Search

Beam Therapeutics Inc

Отворен

СекторЗдравеопазване

26.27 6.44

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

24.6

Максимум

26.68

Ключови измерители
By Trading Economics
Приходи	357M 244M
Продажби	104M 114M
Марж на печалбата	214.091
Служители	511
EBITDA	368M 261M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+90.17% upside

Дивиденти
By Dow Jones
Следващи печалби	4.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-407M 2.5B
Предишно отваряне	19.83
Предишно затваряне	26.27

Настроения в новините

By Acuity

30%

70%

111 / 349 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

16.225 / 20.17 Подкрепа & съпротива

Beam Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.04.2026 г., 20:44 ч. UTC

Печалби

Costco Reports 11% Growth in March Sales

8.04.2026 г., 23:51 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

8.04.2026 г., 23:51 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Talks to End Iran War -- Market Talk

8.04.2026 г., 23:36 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Lower on Likely Technical Correction -- Market Talk

8.04.2026 г., 22:56 ч. UTC

Пазарно говорене

Ramelius Resources May Downgrade Cost Guidance This Month -- Market Talk

8.04.2026 г., 22:45 ч. UTC

Пазарно говорене

Constellation Brands Points to Continuing Challenges Among Hispanic Consumers -- Market Talk

8.04.2026 г., 22:17 ч. UTC

Пазарно говорене

Applied Digital Says Its Holding Out for Quality Customers -- Market Talk

8.04.2026 г., 21:52 ч. UTC

Значими събития в новините

A Closer Look at Iran's 10 Demands -- and Which the U.S. Might Accept -- Update

8.04.2026 г., 21:24 ч. UTC

Печалби

FedEx Freight Aims for 12% Profit Growth. How That Compares to the Leader. -- Barrons.com

8.04.2026 г., 21:01 ч. UTC

Значими събития в новините

Oil Prices Tumble Despite Conflicting Reports About the Strait of Hormuz -- Barrons.com

8.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

8.04.2026 г., 20:43 ч. UTC

Придобивния, сливания и поглъщания

Oracle Is Expressing No Opinion and Is Neutral as to Whether Stockholders Should Tender Their Shrs in Response to TRC's Offer >ORCL

8.04.2026 г., 20:43 ч. UTC

Придобивния, сливания и поглъщания

Oracle Does Not Endorse TRC's Mini-Tender Offer or the Offer Documentation >ORCL

8.04.2026 г., 20:43 ч. UTC

Придобивния, сливания и поглъщания

Oracle: Offer Represents Less Than 0.04% of Outstanding Common Stk >ORCL

8.04.2026 г., 20:42 ч. UTC

Придобивния, сливания и поглъщания

Oracle: TRC Offer Is to Purchase Up to 1M Shrs of Common Stk at $140.50/Shr in Cash >ORCL

8.04.2026 г., 20:42 ч. UTC

Придобивния, сливания и поглъщания

Oracle Received Notice of Unsolicited Mini-Tender Offer by TRC Dated March 24 >ORCL

8.04.2026 г., 20:42 ч. UTC

Придобивния, сливания и поглъщания

Oracle Responds to TRC Cap Mini-Tender Offer

8.04.2026 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

8.04.2026 г., 20:11 ч. UTC

Придобивния, сливания и поглъщания

Intel Corp.: Repurchased 49% Equity Interest in JV Related to Intel's Fab 34 in Ireland >INTC

8.04.2026 г., 20:11 ч. UTC

Придобивния, сливания и поглъщания

Intel Corp.: $14.2B Repurchase Price Financed with Cash on Hand and a Bridge Loan of $6.5B >INTC

8.04.2026 г., 20:11 ч. UTC

Придобивния, сливания и поглъщания

Intel Corp.: Repurchased JV Stake From Apollo-Managed Funds and Affiliates >INTC

8.04.2026 г., 19:44 ч. UTC

Печалби

These Companies Pay 5% Dividend Yields, and They're Hiking Them Too -- Barrons.com

8.04.2026 г., 19:16 ч. UTC

Пазарно говорене

Hogs Follow Cutout Prices Lower -- Market Talk

8.04.2026 г., 19:02 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

8.04.2026 г., 19:02 ч. UTC

Пазарно говорене

Oil Futures Plunge as Cease-Fire Raises Hopes for Restored Supply -- Market Talk

8.04.2026 г., 18:58 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Fall in Line With Slump in Oil -- Market Talk

8.04.2026 г., 18:51 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

8.04.2026 г., 18:51 ч. UTC

Пазарно говорене

Levi Strauss CEO Says Expanded Offerings, DTC Focus Are Working -- Market Talk

8.04.2026 г., 18:14 ч. UTC

Значими събития в новините

Fed Minutes Suggest a Lengthy Iran War Could Lead to Rate Hikes -- Barrons.com

8.04.2026 г., 18:05 ч. UTC

Значими събития в новините

Oil Prices Continue to Tumble After Cease-Fire Despite Slow Reopening of Strait of Hormuz -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Beam Therapeutics Inc Прогноза

Ценова цел

By TipRanks

90.17% нагоре

12-месечна прогноза

Среден 48.38 USD 90.17%

Висок 80 USD

Нисък 24.18 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Beam Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

11

Купи

1

Задържане

0

Продай

Според 12 анализатори, дали борсови рейтинги на Beam Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

16.225 / 20.17Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

All events are bearish.

Настроение

By Acuity

111 / 349 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Други акции от сектора

MDT

Medtronic PLC

88.2

A

Agilent Technologies Inc

115.27

VEEV

Veeva Systems Inc

156.75

HQY

HealthEquity Inc

82.69

TLRY

Tilray Brands Inc

6.75

Live chat